|
1
|
Bassett CA, Donath A, Macagno F, Preisig
R, Fleisch H and Francis MD: Diphosphonates in the treatment of
myositis ossificans. Lancet. 2:8451969. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Selander KS, Mönkkönen J, Karhukorpi EK,
Härkönen P, Hannuniemi R and Väänänen HK: Characteristics of
clodronate-induced apoptosis in osteoclasts and macrophages. Mol
Pharmacol. 50:1127–1138. 1996.PubMed/NCBI
|
|
3
|
Brown DL and Robbins R: Developments in
the therapeutic applications of bisphosphonates. J Clin Pharmacol.
39:651–660. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsai SH, Huang PH, Chang WC, Tsai HY, Lin
CP, Leu HB, Wu TC, Chen JW and Lin SJ: Zoledronate inhibits
ischemia-induced neovascularization by impairing the mobilization
and function of endothelial progenitor cells. PloS One.
7:e410652012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ottewell PD, Woodward JK, Lefley DV, Evans
CA, Coleman RE and Holen I: Anticancer mechanisms of doxorubicin
and zoledronic acid in breast cancer tumor growth in bone. Mol
Cancer Ther. 8:2821–2832. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi Y, Hiraga T, Ueda A, Wang L,
Matsumoto-Nakano M, Hata K, Yatani H and Yoneda T: Zoledronic acid
delays wound healing of the tooth extraction socket, inhibits oral
epithelial cell migration, and promotes proliferation and adhesion
to hydroxyapatite of oral bacteria, without causing osteonecrosis
of the jaw, in mice. J Bone Miner Metab. 28:165–175. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamashita J, Koi K, Yang DY and McCauley
LK: Effect of zoledronate on oral wound healing in rats. Clin
Cancer Res. 17:1405–1414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diel IJ, Bergner R and Grötz KA: Adverse
effects of bisphosphonates: Current issues. J Support Oncol.
5:475–482. 2007.PubMed/NCBI
|
|
9
|
Ruggiero SL, Dodson TB, Assael LA,
Landesberg R, Marx RE and Mehrotra B: American Association of Oral
and Maxillofacial Surgeons: American Association of Oral and
Maxillofacial Surgeons position paper on bisphosphonate-related
osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67 (5
Suppl). 2–12. 2009. View Article : Google Scholar
|
|
10
|
Russell RG: Bisphosphonates: From bench to
bedside. Ann NY Acad Sci. 1068:367–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Allen MR and Burr DB: Mandible matrix
necrosis in beagle dogs after 3 years of daily oral bisphosphonate
treatment. J Oral Maxillofac Surg. 66:987–994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walter C, Al-Nawas B, Grötz KA, Thomas C,
Thüroff JW, Zinser V, Gamm H, Beck J and Wagner W: Prevalence and
risk factors of bisphosphonate-associated osteonecrosis of the jaw
in prostate cancer patients with advanced disease treated with
zoledronate. Eur Urol. 54:1066–1072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reid IR, Bolland MJ and Grey AB: Is
bisphosphonate-associated osteonecrosis of the jaw caused by soft
tissue toxicity? Bone. 41:318–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Walter C, Pabst A, Ziebart T, Klein M and
Al-Nawas B: Bisphosphonates affect migration ability and cell
viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis.
17:194–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giraudo E, Inoue M and Hanahan D: An
amino-bisphosphonate targets MMP-9-expressing macrophages and
angiogenesis to impair cervical carcinogenesis. J Clin Invest.
114:623–633. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Santini D, Vincenzi B, Dicuonzo G,
Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L,
Tirindelli MC, Altomare V, et al: Zoledronic acid induces
significant and long-lasting modifications of circulating
angiogenic factors in cancer patients. Clin Cancer Res.
9:2893–2897. 2003.PubMed/NCBI
|
|
17
|
Cetinkaya BO, Keles GC, Ayas B and Gurgor
P: Effects of risedronate on alveolar bone loss and angiogenesis: A
stereologic study in rats. J Periodontol. 79:1950–1961. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khandelwal VK, Mitrofan LM, Hyttinen JM,
Chaudhari KR, Buccione R, Kaarniranta K, Ravingerová T and
Mönkkönen J: Oxidative stress plays an important role in zoledronic
acid-induced autophagy. Physiol Res. 63:(Suppl 4). S601–S612.
2014.PubMed/NCBI
|
|
19
|
Mizushima N and Levine B: Autophagy in
mammalian development and differentiation. Nat Cell Biol.
12:823–830. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rubinsztein DC, Mariño G and Kroemer G:
Autophagy and aging. Cell. 146:682–695. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang IT, Chou SC and Lin YC: Zoledronic
acid induces apoptosis and autophagy in cervical cancer cells.
Tumour Biol. 35:11913–11920. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ge XY, Yang LQ, Jiang Y, Yang WW, Fu J and
Li SL: Reactive oxygen species and autophagy associated apoptosis
and limitation of clonogenic survival induced by zoledronic acid in
salivary adenoid cystic carcinoma cell line SACC-83. PloS One.
9:e1012072014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin JF, Lin YC, Lin YH, Tsai TF, Chou KY,
Chen HE and Hwang TI: Zoledronic acid induces autophagic cell death
in human prostate cancer cells. J Urol. 185:1490–1496. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lv XH, Zhao DH, Cai SZ, Luo SY, You T, Xu
BL and Chen K: Autophagy plays a protective role in cell death of
osteoblasts exposure to lead chloride. Toxicol Lett. 239:131–140.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bezzi M, Hasmim M, Bieler G, Dormond O and
Rüegg C: Zoledronate sensitizes endothelial cells to tumor necrosis
factor-induced programmed cell death: Evidence for the suppression
of sustained activation of focal adhesion kinase and protein kinase
B/Akt. J Biol Chem. 278:43603–43614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Klionsky DJ, Abeliovich H, Agostinis P,
Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA,
Ballabio A, et al: Guidelines for the use and interpretation of
assays for monitoring autophagy in higher eukaryotes. Autophagy.
4:151–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ichimura Y and Komatsu M: Selective
degradation of p62 by autophagy. Semin Immunopathol. 32:431–436.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pattingre S, Espert L, Biard-Piechaczyk M
and Codogno P: Regulation of macroautophagy by mTOR and Beclin 1
complexes. Biochimie. 90:313–323. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Esteban-Martinez L and Boya P: Autophagic
flux determination in vivo and ex vivo. Methods. 75:79–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leist M and Jäättelä M: Four deaths and a
funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell
Biol. 2:589–598. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moscat J and Diaz-Meco MT: p62 at the
crossroads of autophagy, apoptosis, and cancer. Cell.
137:1001–1004. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shvets E, Fass E and Elazar Z: Utilizing
flow cytometry to monitor autophagy in living mammalian cells.
Autophagy. 4:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wasko BM, Dudakovic A and Hohl RJ:
Bisphosphonates induce autophagy by depleting geranylgeranyl
diphosphate. J Pharmacol Exp Ther. 337:540–546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iwai-Kanai E, Yuan H, Huang C, Sayen MR,
Perry-Garza CN, Kim L and Gottlieb RA: A method to measure cardiac
autophagic flux in vivo. Autophagy. 4:322–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lacy MQ, Dispenzieri A, Gertz MA, Greipp
PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell
SJ, et al: Mayo clinic consensus statement for the use of
bisphosphonates in multiple myeloma. Mayo Clin Proc. 81:1047–1053.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang EP, Kaban LB, Strewler GJ, Raje N and
Troulis MJ: Incidence of osteonecrosis of the jaw in patients with
multiple myeloma and breast or prostate cancer on intravenous
bisphosphonate therapy. J Oral Maxillofac Surg. 65:1328–1331. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fournier P, Boissier S, Filleur S,
Guglielmi J, Cabon F, Colombel M and Clézardin P: Bisphosphonates
inhibit angiogenesis in vitro and testosterone-stimulated vascular
regrowth in the ventral prostate in castrated rats. Cancer Res.
62:6538–6544. 2002.PubMed/NCBI
|
|
39
|
Zhuang W, Qin Z and Liang Z: The role of
autophagy in sensitizing malignant glioma cells to radiation
therapy. Acta Biochim Biophys Sin (Shanghai). 41:341–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
